外陰部痛治療市場-世界の産業規模、シェア、動向、機会、予測、タイプ別、適応症別、プロバイダー別、地域別、競合別、2020年～2030年

外陰部痛治療の世界市場は、2024年に445億8,000万米ドルと評価され、予測期間中のCAGRは8.38％を記録し、2030年までには722億6,000万米ドルに達すると予測されています。

外陰部痛は、外陰部に影響を及ぼす慢性的な疼痛症状であり、多くの場合、灼熱感、刺痛、刺激感、またはヒリヒリさを特徴とします。主に生殖年齢の女性が罹患し、徐々に発症することもあれば突然発症することもあります。正確な原因は不明ですが、ホルモンの変動、感染症、神経の損傷などが原因として考えられます。診断には通常、病歴聴取、身体診察、専門的評価を組み合わせて、他の潜在的原因を除外することが必要です。治療の選択肢は多岐にわたり、外用薬や内服薬、理学療法、カウンセリング、重症例では外科的手術が行われます。外陰部痛に対する認識の高まり、診断ツールの改善、治療オプションの進歩が市場を大きく牽引しています。遠隔医療や、婦人科医、理学療法士、痛みの専門家、精神保健の専門家を統合した集学的治療アプローチの採用が増加していることも、市場の成長をさらに後押ししています。さらに、技術革新に支えられた、より効果的で的を絞った治療法の調査により、外陰部痛患者の個別化ケアへのアクセスが世界的に拡大しています。

主要な市場促進要因

技術の進歩

主要な市場課題

限られた治療オプション

主要な市場動向

患者中心の医療

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の外陰部痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（バイオフィードバック・理学療法、病変内注射、経口治療、外科治療、局所治療）
  • 適応症別（全身性外陰部痛、局所性外陰部痛）
  • プロバイダー別（病院・介護施設、製薬・バイオテクノロジー企業、研究開発センター）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 アジア太平洋の外陰部痛治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の外陰部痛治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の外陰部痛治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の外陰部痛治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの外陰部痛治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の外陰部痛治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Novartis AG
• Endo International Inc
• Teva Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd
• Cipla Inc
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Abbvie Inc
• Zydus Group
• Taro Pharmaceutical Industries Ltd

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Vulvodynia Treatment Market was valued at USD 44.58 billion in 2024 and is projected to reach USD 72.26 billion by 2030, registering a CAGR of 8.38% during the forecast period. Vulvodynia is a chronic pain condition affecting the vulvar region, often characterized by burning, stinging, irritation, or rawness. It primarily affects women of reproductive age and can develop gradually or suddenly. While the exact cause remains unclear, contributing factors may include hormonal fluctuations, infections, or nerve injury. The diagnosis typically involves ruling out other potential causes through a combination of medical history review, physical examinations, and specialized assessments. Treatment options are diverse, encompassing topical and oral medications, physical therapy, counseling, and surgical procedures in severe cases. The growing awareness of vulvodynia, improved diagnostic tools, and advances in therapeutic options are significantly driving the market. Increasing adoption of telemedicine and multidisciplinary care approaches-integrating gynecologists, physiotherapists, pain specialists, and mental health professionals-further supports market growth. Additionally, research into more effective and targeted therapies, supported by technological innovation, is expanding access to personalized care for vulvodynia patients globally.

Key Market Drivers

Technological Advancements

Technological innovations are playing a pivotal role in advancing the diagnosis and treatment of vulvodynia. High-resolution imaging tools such as MRI and ultrasound are increasingly used to assess pelvic anatomy and guide clinical decisions. The rise of telemedicine-particularly following the COVID-19 pandemic-has expanded access to specialist care for vulvodynia patients, especially those in remote areas. Additionally, artificial intelligence (AI) tools are being developed to assist in diagnosis by analyzing clinical data and identifying patterns indicative of vulvodynia. Other notable advancements include biofeedback and electrical stimulation devices used in pelvic floor therapy, targeted drug delivery systems (such as medicated topical creams), and mobile health apps for symptom tracking and patient education. Furthermore, wearable technologies and virtual reality interventions are emerging to help patients manage pain and monitor therapy effectiveness. These innovations are enhancing clinical outcomes and promoting a patient-centric approach to care, fueling the overall growth of the vulvodynia treatment market.

Key Market Challenges

Limited Treatment Options

A major challenge in the vulvodynia treatment market is the limited availability of effective, standardized therapies. Due to the condition's complex and varied nature, patients often undergo a lengthy trial-and-error process to find relief. Treatment outcomes can vary widely among individuals, and medications such as anticonvulsants, antidepressants, or topical anesthetics may not deliver consistent or lasting results. Moreover, some of these drugs can cause adverse effects, complicating the treatment process. Access to non-pharmacological therapies like pelvic floor physical therapy and cognitive behavioral therapy is also inconsistent, particularly in rural or underserved regions. Compounding these issues is the lack of comprehensive understanding of the condition's etiology, which hampers innovation in targeted drug development. Inadequate funding and limited awareness among healthcare providers further delay diagnosis and effective treatment. This shortage of robust treatment options often impacts patients' mental well-being, underscoring the urgent need for broader access to specialized care and research-backed interventions.

Key Market Trends

Patient-Centered Care

The shift toward patient-centered care is becoming a key trend in the vulvodynia treatment market. Healthcare providers are increasingly emphasizing personalized treatment strategies that address not only the physical symptoms but also the psychological and emotional impact of chronic vulvar pain. This approach includes shared decision-making, where patients actively participate in choosing treatment plans tailored to their preferences and lifestyle. Education is also central to this model-patients are encouraged to understand their condition and engage in self-management techniques, such as lifestyle changes and therapy adherence. Multidisciplinary support-including physical therapy, pain management, and mental health services-is integrated to offer a holistic treatment pathway. Additionally, providers are more attuned to patient feedback and committed to respecting individual treatment choices, even when they involve complementary or alternative therapies. By focusing on empowering patients, this trend is improving satisfaction, adherence, and overall health outcomes in vulvodynia care.

Key Market Players

• Novartis AG
• Endo International Inc
• Teva Pharmaceutical Industries Ltd
• Glenmark Pharmaceuticals Ltd
• Cipla Inc
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Zydus Group
• Taro Pharmaceutical Industries Ltd
• Abbvie Inc.

Report Scope:

In this report, the Global Vulvodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvodynia Treatment Market, By Type:

• Biofeedback & Physical Therapy
• Intralesional Injections
• Oral Treatment
• Surgical Treatment
• Topical Treatments

Vulvodynia Treatment Market, By Indication:

• Generalized Vulvodynia
• Localized Vulvodynia

Vulvodynia Treatment Market, By Providers:

• Hospitals & Care Providers
• Pharmaceutical & Biotechnology Companies
• Research & Development Centers

Vulvodynia Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvodynia Treatment Market.

Available Customizations:

Global Vulvodynia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vulvodynia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment, Surgical Treatment, Topical Treatments)
  • 5.2.2. By Indication (Generalized Vulvodynia, Localized Vulvodynia)
  • 5.2.3. By Providers (Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies, Research & Development Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Vulvodynia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Providers
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Vulvodynia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Providers
  • 6.3.2. India Vulvodynia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Providers
  • 6.3.3. Australia Vulvodynia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Providers
  • 6.3.4. Japan Vulvodynia Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Indication
      • 6.3.4.2.3. By Providers
  • 6.3.5. South Korea Vulvodynia Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Indication
      • 6.3.5.2.3. By Providers

7. Europe Vulvodynia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Providers
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Vulvodynia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Providers
  • 7.3.2. Germany Vulvodynia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Providers
  • 7.3.3. Spain Vulvodynia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Providers
  • 7.3.4. Italy Vulvodynia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Providers
  • 7.3.5. United Kingdom Vulvodynia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Providers

8. North America Vulvodynia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Providers
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Vulvodynia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Providers
  • 8.3.2. Mexico Vulvodynia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Providers
  • 8.3.3. Canada Vulvodynia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Providers

9. South America Vulvodynia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Providers
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Vulvodynia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Providers
  • 9.3.2. Argentina Vulvodynia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Providers
  • 9.3.3. Colombia Vulvodynia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Providers

10. Middle East and Africa Vulvodynia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Providers
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Vulvodynia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Providers
  • 10.3.2. Saudi Arabia Vulvodynia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Providers
  • 10.3.3. UAE Vulvodynia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Providers

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Vulvodynia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Novartis AG
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.6. SWOT Analysis
• 16.2. Endo International Inc
• 16.3. Teva Pharmaceutical Industries Ltd
• 16.4. Glenmark Pharmaceuticals Ltd
• 16.5. Cipla Inc
• 16.6. F. Hoffmann-La Roche Ltd
• 16.7. Pfizer Inc
• 16.8. Abbvie Inc
• 16.9. Zydus Group
• 16.10.Taro Pharmaceutical Industries Ltd

17. Strategic Recommendations

18. About Us & Disclaimer